|  |  |  | **1st dose vs. Unvaccinated** | | **3rd dose vs. 2nd dose** | |
| --- | --- | --- | --- | --- | --- | --- |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 8,498 | 8,498 | 2,962 | 2,962 |
| Age | - | Median [Q25 - Q75] | 32.00 [28.00 - 36.00] | 32.00 [28.00 - 36.00] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 899 (10.6%) | 892 (10.5%) | 107 (3.6%) | 109 (3.7%) |
|  | 25 to 39 | N (%) | 6,845 (80.5%) | 6,860 (80.7%) | 2,526 (85.3%) | 2,529 (85.4%) |
|  | 40 to 55 | N (%) | 754 (8.9%) | 746 (8.8%) | 329 (11.1%) | 324 (10.9%) |
| Vaccine brand | Moderna | N (%) | 1,679 (19.8%) | 1,679 (19.8%) | 2,072 (70.0%) | 2,072 (70.0%) |
|  | Pfizer | N (%) | 6,819 (80.2%) | 6,819 (80.2%) | 890 (30.0%) | 890 (30.0%) |
| Trimester | Trimester 1 | N (%) | 2,194 (25.8%) | 2,195 (25.8%) | 882 (29.8%) | 870 (29.4%) |
|  | Trimester 2 | N (%) | 3,485 (41.0%) | 3,456 (40.7%) | 1,261 (42.6%) | 1,276 (43.1%) |
|  | Trimester 3 | N (%) | 2,819 (33.2%) | 2,847 (33.5%) | 819 (27.7%) | 816 (27.5%) |
| Number visits prior year | - | Median [Q25 - Q75] | 17.00 [9.00 - 29.00] | 32.00 [16.00 - 54.00] | 19.00 [10.00 - 34.00] | 34.00 [18.00 - 56.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 2,154 (25.3%) | 1,906 (22.4%) | 596 (20.1%) | 553 (18.7%) |
|  | Heart conditions | N (%) | 170 (2.0%) | 206 (2.4%) | 81 (2.7%) | 71 (2.4%) |
|  | Eclampsia preeclampsia | N (%) | 85 (1.0%) | 94 (1.1%) | 29 (1.0%) | 37 (1.2%) |
|  | Asthma | N (%) | 444 (5.2%) | 527 (6.2%) | 176 (5.9%) | 201 (6.8%) |
|  | Pneumonia | N (%) | 244 (2.9%) | 284 (3.3%) | 80 (2.7%) | 75 (2.5%) |
|  | Hypothyroidism | N (%) | 676 (8.0%) | 753 (8.9%) | 278 (9.4%) | 306 (10.3%) |
|  | Depressive disorder | N (%) | 469 (5.5%) | 491 (5.8%) | 140 (4.7%) | 158 (5.3%) |
|  | Gestational diabetes | N (%) | 499 (5.9%) | 499 (5.9%) | 144 (4.9%) | 137 (4.6%) |
|  | Chronic hypertension | N (%) | 171 (2.0%) | 202 (2.4%) | 63 (2.1%) | 74 (2.5%) |
|  | Anxiety disorder | N (%) | 2,358 (27.7%) | 2,341 (27.5%) | 810 (27.3%) | 763 (25.8%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | 11 (0.1%) | <5 (<5%) | 9 (0.3%) |
| Drugs prior 180 days | Propulsives | N (%) | 331 (3.9%) | 334 (3.9%) | 101 (3.4%) | 70 (2.4%) |
|  | Progestogens | N (%) | 453 (5.3%) | 458 (5.4%) | 192 (6.5%) | 172 (5.8%) |
|  | Antimycotics systemic | N (%) | 38 (0.4%) | 46 (0.5%) | 13 (0.4%) | 12 (0.4%) |
|  | Estrogens | N (%) | 609 (7.2%) | 604 (7.1%) | 158 (5.3%) | 165 (5.6%) |
|  | Antithrombotics | N (%) | 445 (5.2%) | 380 (4.5%) | 267 (9.0%) | 185 (6.2%) |
|  | Antihistamines systemic | N (%) | 1,233 (14.5%) | 1,342 (15.8%) | 450 (15.2%) | 487 (16.4%) |
|  | Antidepressants | N (%) | 403 (4.7%) | 457 (5.4%) | 130 (4.4%) | 144 (4.9%) |
|  | Immunoglobulins | N (%) | 362 (4.3%) | 333 (3.9%) | 122 (4.1%) | 110 (3.7%) |
|  | Analgesics and antipyretics | N (%) | 2,853 (33.6%) | 2,910 (34.2%) | 1,056 (35.7%) | 962 (32.5%) |
|  | Antiinflammatory antirehumatic | N (%) | 1,305 (15.4%) | 1,287 (15.1%) | 498 (16.8%) | 481 (16.2%) |
|  | Antiepileptics | N (%) | 111 (1.3%) | 142 (1.7%) | 40 (1.4%) | 43 (1.5%) |
|  | Antibacterials systemic | N (%) | 1,959 (23.1%) | 1,986 (23.4%) | 663 (22.4%) | 587 (19.8%) |